Selank: Research Overview, Mechanism & Published Studies

What Selank is

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as an analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) originally described in relation to immune function. Selank extends the tuftsin sequence with a Pro-Gly-Pro tripeptide — a stabilizing motif also used in Semax and reported to have biological activity of its own — to resist rapid enzymatic degradation while preserving the parent sequence.

Because it shares no structural relationship with adrenocorticotropic hormone (ACTH) or the melanocortin peptide family, Selank's published research literature is oriented differently than Semax's: the studies compiled below investigate the GABAergic system, enkephalin-degrading enzymes, and, in tuftsin's original tradition, immune-related signaling — rather than melanocortin receptors or neurotrophin expression.

In a research setting, Selank is typically supplied as a lyophilized (freeze-dried) powder for reconstitution and laboratory investigation. It is supplied for laboratory research use only and is not for human consumption.

Pathways published research has investigated

Published studies — spanning rodent gene-expression work, in-vitro enzyme assays, behavioral models, and a set of Russian-language human trials — have investigated Selank in the context of several biological systems. These are descriptions of what researchers have studied, not statements of effect in humans:

GABAergic gene expression in rat frontal cortex. A study examining 84 genes involved in GABAergic neurotransmission found that Selank administration produced significant expression changes in a majority of the genes assayed one hour post-dose, with a reported positive correlation between the gene-expression changes triggered by Selank and by GABA itself — findings the researchers interpreted as consistent with an allosteric interaction at the GABA-A receptor complex rather than direct receptor binding.

Interaction with GABA and antipsychotic co-administration in cultured cells. Follow-up work in human IMR-32 neuroblastoma cells reported that Selank alone had no direct effect on GABAergic-system gene transcription, but that combining Selank with GABA reduced the gene-expression changes GABA produced on its own, while combining Selank with olanzapine amplified olanzapine's effects — a pattern the researchers characterized as indirect, receptor-complex-level modulation rather than a simple additive effect.

Enkephalin-degrading enzyme inhibition. An enzymatic assay in human serum reported that both Semax and Selank inhibited enkephalin-degrading enzymes in vitro, a mechanism the researchers proposed as a possible contributor to the peptides' studied behavioral effects, since enkephalins are endogenous opioid-system signaling peptides.

Immunomodulatory signaling. In keeping with Selank's tuftsin lineage, a published human study examined immune markers in patients with anxiety-asthenic disorders following Selank administration, reporting changes in measured immune parameters in that clinical research setting.

Behavioral and learning models in rodents. A conditioned active-avoidance study reported that Selank activated learning performance in rats characterized as poor learners, with effects reported as comparable in magnitude to the reference nootropic piracetam in that model.

The state of the literature

Selank has a body of published human research behind it, concentrated in Russian-language clinical literature: a study in patients with generalized anxiety disorder and neurasthenia examined efficacy and proposed mechanisms of action for Selank as an investigational anxiolytic agent in that clinical research context. A separate published trial reported on Selank's studied immunomodulatory effects in patients with anxiety-asthenic disorders. A 2019 review synthesizing the broader body of Selank and Selank-fragment research described reported effects across anxiolytic, cognitive, immunostimulatory, and other domains studied in the literature, and proposed that many of these are mediated through the enkephalin system.

It is important to characterize the rest of the picture accurately. Much of the mechanistic and behavioral literature on Selank comes from animal models (rat and cell-based studies) rather than large, independently replicated human trials, and the human clinical studies that do exist are older, smaller, and published primarily in Russian-language journals rather than in the large multi-site trials associated with approved pharmaceuticals. Selank is registered as a pharmaceutical in Russia for specific indications, but it has not been approved by the FDA or any Western regulator as a drug for any use, and it is not a dietary supplement in the United States. The research framing reflects that: studies describe gene-expression changes, enzyme-inhibition data, and findings from a limited published clinical record — not an established, independently validated outcome in the way an FDA-approved therapeutic would be.

This is exactly why credible discussion of Selank stays in the research register — "studies have investigated," "the published trial reported," "the literature describes" — rather than making claims about what the compound does for a person.

How researchers handle it

In laboratory use, Selank is reconstituted from lyophilized powder, commonly with bacteriostatic water, and handled under standard research conditions. Material supplied for research should carry a Certificate of Analysis confirming HPLC-verified purity so that what is being studied is well-characterized.

Go deeper

Selank: mechanism of action in published studies — a closer look at the GABAergic and enkephalin-system pathways above.

Selank vs Semax: what the research compares — how Selank's studied profile differs from the structurally related, commonly co-discussed Semax in the literature.

Selank research FAQ — common questions, answered in a research context.

Research materials

Related compound: Selank — supplied as research-grade lyophilized powder with Certificate of Analysis. Research use only. Not for human consumption.